Contrasting Pro-Dex (PDEX) & iCAD (ICAD)

Pro-Dex (NASDAQ:PDEX) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Earnings & Valuation

This table compares Pro-Dex and iCAD’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pro-Dex $22.47 million 2.55 $1.62 million N/A N/A
iCAD $25.62 million 3.82 -$9.02 million ($0.38) -14.82

Pro-Dex has higher earnings, but lower revenue than iCAD.

Insider & Institutional Ownership

10.5% of Pro-Dex shares are held by institutional investors. Comparatively, 17.2% of iCAD shares are held by institutional investors. 41.7% of Pro-Dex shares are held by insiders. Comparatively, 10.1% of iCAD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Pro-Dex and iCAD, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pro-Dex 0 0 1 0 3.00
iCAD 0 0 0 0 N/A

Pro-Dex currently has a consensus target price of $20.00, indicating a potential upside of 43.47%. Given Pro-Dex’s higher probable upside, equities analysts plainly believe Pro-Dex is more favorable than iCAD.

Risk and Volatility

Pro-Dex has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, iCAD has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Profitability

This table compares Pro-Dex and iCAD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pro-Dex 12.98% 19.69% 14.47%
iCAD -36.24% -47.63% -15.14%

Summary

Pro-Dex beats iCAD on 8 of the 12 factors compared between the two stocks.

About Pro-Dex

Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

About iCAD

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.